Abnova — Investor Presentation 2022

Nov 23, 2022

Abnova (Taiwan) Corp. (4133.TW)

2022 Investor Conference

2022/11/23

==> picture [15 x 137] intentionally omitted <==

Innovate through Integrated Solutions www.abnova.com.tw

==> picture [40 x 40] intentionally omitted <==

==> picture [99 x 54] intentionally omitted <==

Safe Harbor Notice

The contain & estimates of financial information as well as following pages projections market and product developments for future periods. These projections & estimates are based on information currently available which we believe to be reliable, but they involve risks & uncertainties. Our actual results of operations & financial condition may differ significantly from those contained in the projections & estimates. The projections & estimates should not be interpreted as legally binding commitments, but rather as flexible information subject to change occasionally.

==> picture [47 x 246] intentionally omitted <==

2

==> picture [99 x 54] intentionally omitted <==

Our Agenda

1

==> picture [63 x 60] intentionally omitted <==

Abnova Company Profile About us - Our history and archives

2

==> picture [66 x 60] intentionally omitted <==

Abnova Financial Results Financial results, revenue by product

3

==> picture [66 x 61] intentionally omitted <==

Abnova Product Family The latest product development progress in 2022

==> picture [47 x 246] intentionally omitted <==

3

1

==> picture [63 x 59] intentionally omitted <==

Abnova Company Profile

==> picture [47 x 246] intentionally omitted <==

4

==> picture [99 x 54] intentionally omitted <==

Abnova Company Profile

==> picture [311 x 351] intentionally omitted <==

==> picture [335 x 345] intentionally omitted <==

==> picture [47 x 246] intentionally omitted <==

5

6

==> picture [437 x 268] intentionally omitted <==

==> picture [162 x 142] intentionally omitted <==

==> picture [164 x 121] intentionally omitted <==

==> picture [246 x 158] intentionally omitted <==

==> picture [356 x 158] intentionally omitted <==

==> picture [47 x 246] intentionally omitted <==

==> picture [373 x 441] intentionally omitted <==

==> picture [47 x 246] intentionally omitted <==

7

==> picture [483 x 433] intentionally omitted <==

==> picture [47 x 246] intentionally omitted <==

8

2 Abnova Financial Results

==> picture [47 x 246] intentionally omitted <==

9

==> picture [99 x 54] intentionally omitted <==

Consolidated Income Statement

==> picture [703 x 229] intentionally omitted <==

==> picture [47 x 246] intentionally omitted <==

10

==> picture [99 x 54] intentionally omitted <==

Revenue Breakdown by Product

==> picture [66 x 29] intentionally omitted <==

==> picture [269 x 223] intentionally omitted <==

==> picture [422 x 257] intentionally omitted <==

==> picture [47 x 246] intentionally omitted <==

11

3

==> picture [63 x 61] intentionally omitted <==

Abnova Product Family

==> picture [47 x 246] intentionally omitted <==

12

==> picture [99 x 54] intentionally omitted <==

Abnova Product Family

SAM, mRNA, circRNA OM-PBAE, cKK-E12, C12-200 LNP circRNA COVID-19 Vaccine Abnova Product Family mRNA Omicron Vaccine Cytokine RNA LNP Liver Cancer Therapy PsAg RNA LNP Prostate Cancer Vaccine

==> picture [47 x 246] intentionally omitted <==

13

SAM, mRNA, circRNA

==> picture [532 x 331] intentionally omitted <==

==> picture [47 x 246] intentionally omitted <==

14

OM-PBAE, cKK-E12, C12-200 LNP

==> picture [530 x 334] intentionally omitted <==

==> picture [47 x 246] intentionally omitted <==

15

circRNA COVID-19 Vaccine

==> picture [561 x 356] intentionally omitted <==

==> picture [47 x 246] intentionally omitted <==

16

circRNA COVID-19 Vaccine

==> picture [424 x 39] intentionally omitted <==

Data :

S1+S2 circRNA Vaccine induce High Titer Antibody Response Against SARS-CoV2 Pseudovirus

==> picture [239 x 149] intentionally omitted <==

==> picture [239 x 149] intentionally omitted <==

==> picture [240 x 149] intentionally omitted <==

==> picture [47 x 246] intentionally omitted <==

17

mRNA Omicron Vaccine

Background

SARS-CoV-2 Omicron variant was first identified in mid-November 2021 and rapidly became the dominant variant in many countries. Spread of the Omicron variant, which led to increased hospitalizations for COVID-19, generated concern about immune evasion and the duration of protection from vaccines developed earlier. Abnova is developing new vaccines for Omicron variant using mRNA vaccine technologies. The structure of the mRNA includes a 5’ cap, the 5’ untranslated region (UTR), the Open Reading Frame (ORF), the 3’ UTR, and the 3’ polyA tail. Synthetic RNA nucleobase N1-methylpseudouridine, which reduces immunogenicity and enhances protein expression, is used in in vitro transcription for the production of mRNA vaccines.

==> picture [307 x 233] intentionally omitted <==

==> picture [421 x 231] intentionally omitted <==

==> picture [47 x 246] intentionally omitted <==

18

mRNA Omicron Vaccine

==> picture [398 x 374] intentionally omitted <==

==> picture [47 x 246] intentionally omitted <==

19

Cytokine RNA LNP Liver Cancer Therapy

==> picture [541 x 375] intentionally omitted <==

==> picture [47 x 246] intentionally omitted <==

20

PsAg RNA LNP Prostate Cancer Vaccine

==> picture [615 x 373] intentionally omitted <==

==> picture [47 x 246] intentionally omitted <==

21

==> picture [169 x 211] intentionally omitted <==

Thank You

Abnova Innovate through Integrated Solutions

==> picture [175 x 71] intentionally omitted <==

==> picture [380 x 77] intentionally omitted <==

==> picture [280 x 72] intentionally omitted <==

==> picture [40 x 40] intentionally omitted <==